Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
A legfontosabb adatok
- Ki végzi
- Baystate Medical Center
- Hol
- Springfield (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 424 fő, tervezett
- Kezdés
- 2022. nov. 3.
- Várható befejezés
- 2027. dec. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Enhanced Usual Care (EUC)
- Nurse Practitioner Tobacco Treatment Team (NPT3)
- A regiszteradat frissítve
- 2026. október 1.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- Admitted to Baystate Medical Center in Springfield, MA with a cardiac or pulmonary disease diagnosis will be eligible to participate in this trial
- Patients who smoke cigarettes
- Speak English; We will include any patients with the following diagnoses or procedures from Baystate Medical Center in Springfield, MA:
- myocardial infarction
- coronary artery bypass grafting surgery
- heart valve surgery
- percutaneous coronary intervention (PCI)
- acute coronary syndrome
- heart failure
- chronic obstructive pulmonary disease (COPD)
- asthma exacerbation
Ki nem vehet részt
- We will exclude pregnant or nursing women, patients with current suicidal ideation, planned discharge to hospice or expected survival <6 months, or concurrent use of daily smoked marijuana, because this can increase exhaled carbon monoxide levels, which would confound biochemical confirmation
Helyszínek itt: Egyesült Államok
- Baystate Medical CenterSpringfield, Egyesült ÁllamokContact: Quinn Pack, MDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Tobacco use remains the leading cause of death in the United States and contributes to more than 7 million hospitalizations annually. Being admitted to the hospital offers the perfect opportunity to support smoking cessation. Patients are motivated to quit because of their current illness and societal guidelines recommend clinicians should counsel patients and prescribe smoking cessation pharmacotherapy (SCP) to virtually all smokers.
A teljes eredeti leírásKevesebb
However, only 22% of patients are prescribed SCP while hospitalized, and only 1% are prescribed medications compatible with current guidelines. This failure is part of the reason 70-80% of hospitalized smokers eventually relapse. The relapse typically occurs within a few days of hospital discharge - well before outpatient follow-up can occur.
The investigators aim to improve smoking cessation treatment and guideline adherence by utilizing the opportunity that hospitalization provides. The investigators have created a tobacco treatment team (T3) to overcome physicians' and patients' low use of current guideline smoking cessation medications. The team members are trained in tobacco treatment and will be led by a nurse practitioner (NPT3). The team will work together and 1) prescribe individually tailored and guideline-concordant SCP; 2) counsel and motivate patients to use SCP properly; and 3) manage a mobile phone-based text-messaging system to keep patients motivated and adherent to SCP. Our preliminary data suggest that such an approach is workable and acceptable to patients, physicians, and hospital administrators.
The investigators will recruit 424 patients in the hospital who smoke with cardiopulmonary disease. These patients will be randomized to receive either usual care or personalized care with the NPT3 team. The investigators will compare rates of guideline-concordant SCP use at 1 week and exhaled carbon monoxide (eCO) verified smoking cessation at 6 months between patients randomized to the NPT3 team vs. usual care.
The investigators will also measure the project's economic value from a hospital and payer perspective. Understanding the economic value will better inform hospital and insurance policies and sustainability. Finally, acceptability, generalizability, and sustainability measures will be assessed through qualitative interviews with patients, providers, and hospital leadership.
A vizsgálat 2 csoportja
- Enhanced usual care (EUC)Már használt kezelés, összehasonlításként
The investigators will administer the enhanced usual care intervention to randomized patients.
- Personalized Care: Nurse Practitioner led Tobacco Treatment Team (NPT3)A vizsgált kezelés
The investigators will administer the personalized care NPT3 intervention to randomized patients.
Kezelés: Nurse Practitioner Tobacco Treatment Team (NPT3)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Implementing Effective Smoking Cessation Pharmacotherapy for Hospitalized Smokers With Cardiopulmonary Disease
- A regiszteradat frissítve
- 2026. október 1.